EUVIMEDEUVIMED entdecken
VergleichsstudieOpen Access · CC BY 4.0

Menopausal symptoms in breast cancer survivors on adjuvant endocrine therapy compared with those of menopausal women

Giorgia Asinaro, Claudia Massarotti, Anjeza Xholli, Ambrogio P Londero, Matteo Lambertini, Paola Anserini, Lucia Del Mastro, Angelo Cagnacci

Maturitas · 2025

DOI: 10.1016/j.maturitas.2024.108143 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Maturitas, 2025. Verfasst von Giorgia Asinaro und 7 weiteren Autor:innen. Beteiligte Einrichtung: IRCCS Ospedale Policlinico San Martino, Largo R. Benzi 5, 16132 Genoa, Italy; Department of Neurosciences, Rehabilitation, Ophthalmology, Genetics an…. Hauptthemen laut MEDLINE: Breast Neoplasms, Tamoxifen, Cancer Survivors, Aromatase Inhibitors. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVES: To compare menopausal symptoms of breast cancer survivors on adjuvant endocrine therapy with those of menopausal women. STUDY DESIGN: In a retrospective nested case-control study menopausal symptoms were compared of breast cancer survivors in pre-, peri- or post-menopause at the time of diagnosis, on tamoxifen or an aromatase inhibitor, plus a gonadotrophin-releasing hormone analogue, if pre- or peri-menopausal, and age-matched control women either in the late peri-menopause, or in surgical or in physiological post-menopause on no hormone replacement therapy. Differences between women on tamoxifen and those on aromatase inhibitors were also evaluated. Weighted and non-weighted t-tests, chi-square tests, and linear or logistic regressions were applied as appropriate. MAIN OUTCOME MEASURES: Score on the Greene's Climacteric Scale and so of its subscales evaluating vasomotor, anxiety, depression, somatisation and sexuality symptoms. RESULTS: A total of 99 breast cancer survivors (45 on tamoxifen, 54 on aromatase inhibitors) and 554 controls (173 in late perimenopause, 353 in natural and 28 in surgical menopause) were enrolled. The score on the Greene's Climacteric Scale was similar in cases and controls (means ± standard deviation) (21.3 ± 10.4 vs. 22.8 ± 11.5, p = 0.199), as were the subscale scores for vasomotor symptoms, anxiety, and somatisation. The depression score was lower (4.63 ± 3.3 vs. 5.98 ± 3.8; p = 0.001) in breast cancer survivors on adjuvant endocrine therapy, mainly due to a lower score of -2.132 (95 % confidence interval - 3.858/-0.407; p = 0.016) for users of aromatase inhibitors. The sexuality score was higher (1.76 ± 1.1 vs. 1.50 ± 1.1, p = 0.011) than in controls. Differences remained significant when corrected for age, menarche, body mass index, menopausal status (peri- or post-), type of menopause (natural, surgical), use of gonadotrophin-releasing hormone analogues, years of amenorrhea, smoking, alcohol use, and for breast radiotherapy, chemotherapy, tamoxifen or aromatase inhibitors. Among breast cancer survivors, women on aromatase inhibitors had lower scores for anxiety (5.75 ± 2.5vs.5.75 ± 2.5; p = 0.045) and depression (3.89 ± 2.5 vs. 5.13 ± 3.6; p = 0.046) than women on tamoxifen. CONCLUSIONS: In breast cancer survivors, adjuvant therapy induces symptoms similar in type and intensity to those of symptomatic menopausal women. Compared with menopausal women, breast cancer survivors, particularly those on aromatase inhibitors, appear to experience less severe depressive symptoms.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsTamoxifenCancer SurvivorsAromatase InhibitorsMenopauseHot FlashesAntineoplastic Agents, HormonalHumansFemaleMiddle AgedRetrospective StudiesCase-Control StudiesChemotherapy, AdjuvantDepressionAnxietyAgedAdultGonadotropin-Releasing Hormone

Stichwörter der Autor:innen

AnxietyAromatase inhibitorsBreast cancerDepressionEndocrine adjuvant therapyHot flushesMenopause symptomsTamoxifen

Substanzen

TamoxifenAromatase InhibitorsAntineoplastic Agents, HormonalGonadotropin-Releasing Hormone

Autor:innen und Institutionen

  • IRCCS Ospedale Policlinico San Martino, Largo R. Benzi 5, 16132 Genoa, Italy; Department of Neurosciences, Rehabilitation, Ophthalmology, Genetics and Maternal and Child Health (DINOGMI Department), University of Genoa,…
  • IRCCS Ospedale Policlinico San Martino, Largo R. Benzi 5, 16132 Genoa, Italy.
  • Department of Neurosciences, Rehabilitation, Ophthalmology, Genetics and Maternal and Child Health (DINOGMI Department), University of Genoa, Largo R. Benzi 5, 16132 Genoa, Italy; Obstetrics and Gynecology Unit, IRCCS I…
  • Department of Internal Medicine and Medical Specialties (DiMI), School of Medicine, University of Genoa, Largo R. Benzi 5, 16132 Genoa, Italy; Department of Medical Oncology, UO Clinica di Oncologia Medica, IRCCS Ospeda…
  • IRCCS Ospedale Policlinico San Martino, Largo R. Benzi 5, 16132 Genoa, Italy. Electronic address: angelo.cagnacci@unige.it.

Zitieren

APA

Asinaro, G., Massarotti, C., Xholli, A., Londero, A. P., Lambertini, M., Anserini, P., Del Mastro, L., & Cagnacci, A. (2025). Menopausal symptoms in breast cancer survivors on adjuvant endocrine therapy compared with those of menopausal women. Maturitas. https://doi.org/10.1016/j.maturitas.2024.108143

Vancouver

Asinaro G, Massarotti C, Xholli A, Londero AP, Lambertini M, Anserini P, et al. Menopausal symptoms in breast cancer survivors on adjuvant endocrine therapy compared with those of menopausal women. Maturitas. 2025. doi:10.1016/j.maturitas.2024.108143

BibTeX
@article{Asinaro2025,
  author = {Asinaro, Giorgia and Massarotti, Claudia and Xholli, Anjeza and Londero, Ambrogio P and Lambertini, Matteo and Anserini, Paola and Del Mastro, Lucia and Cagnacci, Angelo},
  title = {Menopausal symptoms in breast cancer survivors on adjuvant endocrine therapy compared with those of menopausal women},
  journal = {Maturitas},
  year = {2025},
  doi = {10.1016/j.maturitas.2024.108143}
}
Kostenlos starten →